Abstract: A passenger rest cabin situated in the overhead crown area of an aircraft provides individual rest compartments along either lateral side of a central longitudinal corridor of limited height. The corridor and entrance thereto is configured to minimize the risk of claustrophobia by providing sensory preparation systems and techniques. Sensory preparation including transitional compartments with variations in video, lighting and ventilation are presented to the passenger to create a more inviting space. The limited height corridor is equipped with a series of handholds, sized and spaced according to the size of the average passenger, to mitigate the strain of traversing the corridor in a bent over position.

Abstract: A bi-directional entry vestibule for a passenger aircraft provides passenger access to overhead rest cabins and lower-lobe rest cabins (e.g., on a lower cargo deck) via separate enclosed chambers incorporating ascending and descending staircases respectively. The ascent and descent chambers may be accessed from the main passenger cabin via access doors (one door or separate doors); the ascending and descending access doors may be on opposing sides of the aircraft (e.g., accessible from port-side and starboard-side aisles) or adjacent to each other and accessible via the same aisle. The ascent chamber may include a further transitional space transitioning into an overhead corridor-based cabin, the transitional space including a crew station comprising a fold-down jump seat, communications equipment, and emergency supply storage.

Abstract: Passenger rest compartments may be incorporated into remote areas of an aircraft, either in the overhead crown region or in lower lobe cargo decks. Each passenger rest compartment includes two-way audio communication with the flight deck and non-intrusive non-visual monitoring of the compartments and surrounding environment to determine passenger presence, absence, and general well-being as well as environmental safety. Rest compartments may be integrated into rest cabins in the overhead or lower lobe areas, the rest cabins accessible from the main passenger cabin via an entry vestibule providing dedicated enclosed paths to the overhead and lower cabins. Additional deployable egress hatches may allow passengers to rapidly return to the main deck from the overhead and lower lobe cabins in the event of an emergency. Selected passenger seats (e.g., partitioned or other premium seats) may include private access to passenger rest compartments.

Abstract: The present invention provides a method of reducing the quantity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quantity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Abstract: A system may include a vestibule disposed in a passenger cabin of an aircraft, the vestibule including a staircase for accessing a passenger rest cabin, the passenger rest cabin implemented above or below the passenger cabin of the aircraft. The system may also include a plurality of passenger rest compartments implemented in the passenger rest cabin, each of the plurality of the passenger rest compartments including a bed and a passenger service unit (PSU).

Abstract: A passenger rest cabin situated in the overhead crown area of an aircraft provides individual rest compartments along either lateral side of a central longitudinal corridor of limited height. The corridor and entrance thereto is configured to minimize the risk of claustrophobia by providing sensory preparation systems and techniques. Sensory preparation including transitional compartments with variations in video, lighting and ventilation are presented to the passenger to create a more inviting space. The limited height corridor is equipped with a series of handholds, sized and spaced according to the size of the average passenger, to mitigate the strain of traversing the corridor in a bent over position.

Abstract: Passenger rest compartments may be incorporated into remote areas of an aircraft, either in the overhead crown region or in lower lobe cargo decks. Each passenger rest compartment includes two-way audio communication with the flight deck and non-intrusive non-visual monitoring of the compartments and surrounding environment to determine passenger presence, absence, and general well-being as well as environmental safety. Rest compartments may be integrated into rest cabins in the overhead or lower lobe areas, the rest cabins accessible from the main passenger cabin via an entry vestibule providing dedicated enclosed paths to the overhead and lower cabins. Additional deployable egress hatches may allow passengers to rapidly return to the main deck from the overhead and lower lobe cabins in the event of an emergency. Selected passenger seats (e.g., partitioned or other premium seats) may include private access to passenger rest compartments.

Abstract: A bi-directional entry vestibule for a passenger aircraft provides passenger access to overhead rest cabins and lower-lobe rest cabins (e.g., on a lower cargo deck) via separate enclosed chambers incorporating ascending and descending staircases respectively. The ascent and descent chambers may be accessed from the main passenger cabin via access doors (one door or separate doors); the ascending and descending access doors may be on opposing sides of the aircraft (e.g., accessible from port-side and starboard-side aisles) or adjacent to each other and accessible via the same aisle. The ascent chamber may include a further transitional space transitioning into an overhead corridor-based cabin, the transitional space including a crew station comprising a fold-down jump seat, communications equipment, and emergency supply storage.

Abstract: An aircraft suite may include a passenger compartment disposed on a main deck of an aircraft. The passenger compartment may be partitioned from a main passenger cabin of the main deck by at least one bulkhead. The passenger compartment may include an aircraft seat and a hatch set within an opening in a floor of the passenger compartment. The aircraft suite may include a lower lobe rest compartment integrated in a cargo deck below the main deck. The lower lobe rest compartment may be proximate to the passenger compartment. The lower lobe rest compartment may include a passenger rest compartment and a device proximate to the hatch. The device may be configured to assist a passenger to at least one of descend into the lower lobe rest compartment from the passenger compartment, or ascend into the passenger compartment from the lower lobe rest compartment, via the hatch.

Abstract: The present invention provides a method of reducing the quantity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quantity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Abstract: The present invention provides a method of reducing the quantity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quantity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Abstract: The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Abstract: The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Abstract: The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Abstract: The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.